Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AED downclassification?

This article was originally published in The Gray Sheet

Executive Summary

FDA may ask its Circulatory System Devices Panel to discuss the downclassification of automatic external defibrillators to Class II, the agency announces in the Oct. 28 Federal Register. The agency urges stakeholders to submit new safety and efficacy data on AEDs, currently designated Class III devices. A final rule downclassifying arrhythmia detectors and alarms to Class II with special controls, along with an accompanying guidance, also was issued Oct. 28. FDA announced its plans to reclassify arrhythmia detectors and alarms in December 2002, responding to petitions from AdvaMed, Quinton Instrument and Zymed Medical Instrumentation (1"The Gray Sheet" Dec. 23, 2002, p. 24)...

You may also be interested in...



AEDs Separated From Arrhythmia Detector, Alarms Under Proposed Rule

FDA intends to recommend automated external defibrillators (AEDs) for reclassification "at a later time," according to a proposed rule downclassifying arrhythmia detectors and alarms from Class III to Class II with special controls

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel